Ensartinib (X-396), a second-generation ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation study.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21122-e21122 ◽  
Author(s):  
Wenfeng Fang ◽  
Yuxiang Ma ◽  
Jianjin Huang ◽  
Yang Zhang ◽  
Benyan Zou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dose Escalation ◽  
Second Generation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Dose Escalation Study ◽  
Alk Positive

Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer

2015 ◽  
Vol 21 (2) ◽  
pp. 240-247 ◽  
Author(s):  
Kyoichi Kaira ◽  
Noriaki Sunaga ◽  
Hisao Imai ◽  
Yosuke Kamide ◽  
Yasuhiko Koga ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dose Escalation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Dose Escalation Study ◽  
Previously Treated
Sign in / Sign up

Export Citation Format

Share Document